Westchester Capital Management (New York)’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Westchester Capital Management (New York)’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.2M	Sell	581,790 -1,087,210	-65%	-$11.5M	0.3%	65
2026 Q1	$17.5M	Hold	1,669,000	–	–	0.79%	20
2025 Q4	$17.3M	Hold	1,669,000	–	–	0.73%	26
2025 Q3	$17.1M	Hold	1,669,000	–	–	0.78%	21
2025 Q2	$17M	Buy	1,669,000 +690,000	+70%	+$6.98M	0.89%	20
2025 Q1	$9.81M	Buy	+979,000	New	+$9.79M	0.51%	39

Other funds holding DMAA

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

RLH Capital Great Neck, New York $209M AUM

Westchester Capital Management (New York)'s DMAA Position: Q2 2026 in Review

Westchester Capital Management (New York) reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 65% in Q2 2026, selling an estimated $11.5M and leaving 581,790 shares worth $6.2M. The position accounts for 0.3% of the portfolio, ranked #65.

Westchester Capital Management (New York) first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $17.5M in Q1 2026. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

Westchester Capital Management (New York) held 581,790 shares of Drugs Made In America Acquisition Corp worth $6.2M as of Q2 2026.
Westchester Capital Management (New York) sold 1,087,210 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $11.5M.
Drugs Made In America Acquisition Corp made up 0.3% of Westchester Capital Management (New York)'s portfolio in Q2 2026, its #65 holding.
Westchester Capital Management (New York) first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
Westchester Capital Management (New York)'s Drugs Made In America Acquisition Corp position peaked at $17.5M in Q1 2026.
18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.